Pub Date : 2021-12-21DOI: 10.33978/2307-3586-2021-17-40-6-10
I. Ilovayskaya
The assessment of the quality of life related to health (HRQoL) is an important parameter that informs the doctor about how the patient interacts with his illness in everyday life and how he reacts to certain aspects related to the disease. In addition to medical problems related to the consequences of the disease and treatment, the patient's expectations regarding the treatment, his subjective assessment of what is happening and the cultural level, as well as related life events, affect the HRQoL. This is especially important for patients with chronic diseases requiring long-term treatment, such as acromegaly. According to various studies, the normalization of hormonal parameters in acromegaly does not lead to a complete restoration of HRQoL. On the one hand, in patients with acromegaly, the HRQoL is worse than in the general population, and first of all it affects the area of physical manifestations. So, the indicators of appearance, general health and physical activity are most often affected. On the other hand, various parameters of the quality of life questionnaires for acromegaly may be more sensitive to detect changes in the condition of patients during treatment, even with optimal indicators of insulin-like growth factor 1. Further study of the relationship between the parameters of quality of life and changes in hormonal status should be the key to improving the long-term prognosis of treatment.
{"title":"Health-Related Quality of Life in Patients with Acromegaly: New Treatment Focus","authors":"I. Ilovayskaya","doi":"10.33978/2307-3586-2021-17-40-6-10","DOIUrl":"https://doi.org/10.33978/2307-3586-2021-17-40-6-10","url":null,"abstract":"The assessment of the quality of life related to health (HRQoL) is an important parameter that informs the doctor about how the patient interacts with his illness in everyday life and how he reacts to certain aspects related to the disease. In addition to medical problems related to the consequences of the disease and treatment, the patient's expectations regarding the treatment, his subjective assessment of what is happening and the cultural level, as well as related life events, affect the HRQoL. This is especially important for patients with chronic diseases requiring long-term treatment, such as acromegaly. According to various studies, the normalization of hormonal parameters in acromegaly does not lead to a complete restoration of HRQoL. On the one hand, in patients with acromegaly, the HRQoL is worse than in the general population, and first of all it affects the area of physical manifestations. So, the indicators of appearance, general health and physical activity are most often affected. On the other hand, various parameters of the quality of life questionnaires for acromegaly may be more sensitive to detect changes in the condition of patients during treatment, even with optimal indicators of insulin-like growth factor 1. Further study of the relationship between the parameters of quality of life and changes in hormonal status should be the key to improving the long-term prognosis of treatment.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82550980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-17DOI: 10.33978/2307-3586-2021-17-34-16-21
A. L. Guseva
The article deals with diseases manifested by episodic vestibular syndrome in the form of dizziness attacks of varying duration. Presented modern clinical criteria for diagnosis and principles of effective therapy of benign paroxysmal positional vertigo, vestibular migraine, Meniere's disease, upper semicircular canal degeneration, vestibular paroxysmia, Mal de Debarquement syndrome, etc.
{"title":"Vertigo Attacks: Differential Diagnosis and Approaches to Therapy","authors":"A. L. Guseva","doi":"10.33978/2307-3586-2021-17-34-16-21","DOIUrl":"https://doi.org/10.33978/2307-3586-2021-17-34-16-21","url":null,"abstract":"The article deals with diseases manifested by episodic vestibular syndrome in the form of dizziness attacks of varying duration. Presented modern clinical criteria for diagnosis and principles of effective therapy of benign paroxysmal positional vertigo, vestibular migraine, Meniere's disease, upper semicircular canal degeneration, vestibular paroxysmia, Mal de Debarquement syndrome, etc.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"2012 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73867616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-17DOI: 10.33978/2307-3586-2021-17-34-8-14
M. Putilina
Acute cerebrovascular accidents are the third leading cause of death and disability in the world. Effective strategies for the prevention of recurrent vascular accidents include the elimination of all risk factors, including new coronavirus infection (COVID-19). Secondary prevention strategies should be the same for all patients with ischemic stroke and TIA. Effective strategies to prevent recurrent vascular accidents include reducing the risk associated with hypertension (high systolic blood pressure), elevated lipid levels, diabetes (high fasting plasma glucose), smoking, low physical activity, unhealthy diets, and abdominal obesity (high weight body). In a pandemic, it is advisable to pay attention to the groups of drugs that have an antithrombotic effect (dipyridamole).
{"title":"Secondary Prevention of Ischemic Stroke in a Pandemic of the New Coronavirus Infection COVID-19: Paradigms and Collisions","authors":"M. Putilina","doi":"10.33978/2307-3586-2021-17-34-8-14","DOIUrl":"https://doi.org/10.33978/2307-3586-2021-17-34-8-14","url":null,"abstract":"Acute cerebrovascular accidents are the third leading cause of death and disability in the world. Effective strategies for the prevention of recurrent vascular accidents include the elimination of all risk factors, including new coronavirus infection (COVID-19). Secondary prevention strategies should be the same for all patients with ischemic stroke and TIA. Effective strategies to prevent recurrent vascular accidents include reducing the risk associated with hypertension (high systolic blood pressure), elevated lipid levels, diabetes (high fasting plasma glucose), smoking, low physical activity, unhealthy diets, and abdominal obesity (high weight body). In a pandemic, it is advisable to pay attention to the groups of drugs that have an antithrombotic effect (dipyridamole).","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83083280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-09DOI: 10.33978/2307-3586-2021-17-35-6-10
P. Konnov, A. A. Arsenieva
At the present time, dermatologists’ arsenal has been significantly enriched with new highly effective drugs able to improve significantly the treatment of chronic immune-dependent dermatoses, in particular – atopic dermatitis and microbial eczema. The article discusses topical external agents for the treatment of patients with chronic dermatoses.
{"title":"The Effectiveness of Topical Drugs with a Personalized Approach in the Treatment of Chronic Dermatoses","authors":"P. Konnov, A. A. Arsenieva","doi":"10.33978/2307-3586-2021-17-35-6-10","DOIUrl":"https://doi.org/10.33978/2307-3586-2021-17-35-6-10","url":null,"abstract":"At the present time, dermatologists’ arsenal has been significantly enriched with new highly effective drugs able to improve significantly the treatment of chronic immune-dependent dermatoses, in particular – atopic dermatitis and microbial eczema. The article discusses topical external agents for the treatment of patients with chronic dermatoses.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81346113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-15DOI: 10.33978/2307-3586-2021-17-28-36-45
Y. Sandler, E. Vinnitskaya
Dyslipidemia is one of the main risk factors for the development of cardiovascular diseases (CVD), which remain the leading cause of death worldwide. Lipid level control is the most effective strategy for the prevention of CVD and its complications (CVC). Statins are the first-line drugs of hypolipidemic therapy. Dyslipidemia is often found in patients with chronic liver diseases (CLD). From a clinical point of view, a number of CLD have an increased risk of CVD. Due to insufficient awareness of doctors about the possibilities of using statin and non-statin lipid-lowering therapy in patients with CLD, the possibility of treating CVD and reducing the risk of CVC in this category of patients is often missed. The purpose of the review is to study modern approaches to lipid-lowering therapy (statin and non-statin) in patients with CVD of various etiologies, including at the stage of liver cirrhosis (LC). Conclusion. CLD should not be considered as a contraindication to the use of statins and other lipid-lowering drugs. Pleiotropic effects of statins, in addition to hypolipidemic action, create new prospects for their use in patients with CLD. Hypolipidemic therapy is recommended for patients with CLD (including at the stage of compensated LC), if they have dyslipidemia and an increased risk of CVD. It is important to compare the benefits and risks of prescribing statins in patients with CLD
{"title":"Hypolipidemic Therapy in Patients with Chronic Liver Diseases: What Should a Gastroenterologist Know","authors":"Y. Sandler, E. Vinnitskaya","doi":"10.33978/2307-3586-2021-17-28-36-45","DOIUrl":"https://doi.org/10.33978/2307-3586-2021-17-28-36-45","url":null,"abstract":"Dyslipidemia is one of the main risk factors for the development of cardiovascular diseases (CVD), which remain the leading cause of death worldwide. Lipid level control is the most effective strategy for the prevention of CVD and its complications (CVC). Statins are the first-line drugs of hypolipidemic therapy. Dyslipidemia is often found in patients with chronic liver diseases (CLD). From a clinical point of view, a number of CLD have an increased risk of CVD. Due to insufficient awareness of doctors about the possibilities of using statin and non-statin lipid-lowering therapy in patients with CLD, the possibility of treating CVD and reducing the risk of CVC in this category of patients is often missed. The purpose of the review is to study modern approaches to lipid-lowering therapy (statin and non-statin) in patients with CVD of various etiologies, including at the stage of liver cirrhosis (LC). Conclusion. CLD should not be considered as a contraindication to the use of statins and other lipid-lowering drugs. Pleiotropic effects of statins, in addition to hypolipidemic action, create new prospects for their use in patients with CLD. Hypolipidemic therapy is recommended for patients with CLD (including at the stage of compensated LC), if they have dyslipidemia and an increased risk of CVD. It is important to compare the benefits and risks of prescribing statins in patients with CLD","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75840300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-15DOI: 10.33978/2307-3586-2021-17-28-54-60
A. O. Bueverov, P. Bogomolov, V. Syutkin
Hepatocellular cancer (HCC) usually develops against the background of chronic liver disease. Until recently, the most common etiology of HCC was infection with hepatitis C virus (HCV). The appearance of direct-acting antiviral drugs (DAAD) has become a big breakthrough in the treatment of HCV infection. A stable virological response can now be achieved in almost all treated patients, even in people at high risk of HCC, primarily with cirrhosis of the liver. At the same time, reports gradually began to accumulate about the continued risk of malignant transformation after successful therapy of DAAD. Simultaneously with the decrease in the burden of cirrhosis caused by HCV, the etiological role of non-alcoholic fatty liver disease (NAFLD) has sharply increased. Moreover, in a significant part of patients with NAFLD, HCC is formed at the pre-cirrhotic stage. These changes in the etiology and epidemiology of HCC suggest the revision of patient management tactics
{"title":"Risk Factors and Hepatocellular Cancer Screening After Hepatitis C Virus Eradication","authors":"A. O. Bueverov, P. Bogomolov, V. Syutkin","doi":"10.33978/2307-3586-2021-17-28-54-60","DOIUrl":"https://doi.org/10.33978/2307-3586-2021-17-28-54-60","url":null,"abstract":"Hepatocellular cancer (HCC) usually develops against the background of chronic liver disease. Until recently, the most common etiology of HCC was infection with hepatitis C virus (HCV). The appearance of direct-acting antiviral drugs (DAAD) has become a big breakthrough in the treatment of HCV infection. A stable virological response can now be achieved in almost all treated patients, even in people at high risk of HCC, primarily with cirrhosis of the liver. At the same time, reports gradually began to accumulate about the continued risk of malignant transformation after successful therapy of DAAD. Simultaneously with the decrease in the burden of cirrhosis caused by HCV, the etiological role of non-alcoholic fatty liver disease (NAFLD) has sharply increased. Moreover, in a significant part of patients with NAFLD, HCC is formed at the pre-cirrhotic stage. These changes in the etiology and epidemiology of HCC suggest the revision of patient management tactics","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82371033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-15DOI: 10.33978/2307-3586-2021-17-28-72-78
E. Dubtsova, L. Vinokurova
Abdominal pain syndrome is widespread in the population. Pain can be both organic and functional in nature. Pain cider in chronic pancreatitis is characterized by a variety of manifestations, it depends not only on the severity of inflammation, the presence and absence of complications, but as well on individual susceptibility. Due to the fact that abdominal pain in chronic pancreatitis is multicomponent, its treatment requires the careful and deliberate approach using a variety of techniques
{"title":"Some Aspects of Differential Diagnosis and Treatment of Pain Syndrome in Chronic Pancreatitis","authors":"E. Dubtsova, L. Vinokurova","doi":"10.33978/2307-3586-2021-17-28-72-78","DOIUrl":"https://doi.org/10.33978/2307-3586-2021-17-28-72-78","url":null,"abstract":"Abdominal pain syndrome is widespread in the population. Pain can be both organic and functional in nature. Pain cider in chronic pancreatitis is characterized by a variety of manifestations, it depends not only on the severity of inflammation, the presence and absence of complications, but as well on individual susceptibility. Due to the fact that abdominal pain in chronic pancreatitis is multicomponent, its treatment requires the careful and deliberate approach using a variety of techniques","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80711490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-15DOI: 10.33978/2307-3586-2021-17-28-16-22
V. L. Korobka, V. Pasechnikov, R. V. Korobka, A. Shapovalov
Objectives of the study: to analyze the survival rate of patients who received and did not receive various drugs of the class of non-selective beta-blockers (NSBB) while waiting for liver transplantation (LT) on the waiting list for liver transplantation (WLLT), depending on the presence or absence of a "therapeutic window" for the appointment of NSBB; to determine risk factors for death when prescribing various representatives of the NSBB class in patients with refractory ascites (RA). Material and methods. The retrospective case-control study was conducted. The "case" group included 278 adult patients with decompensated liver diseases of various etiologies included in the WLLT, who were treated with NSBB while waiting for LT. The "control" group consisted of 72 patients with decompensated liver diseases of various etiologies included in the WLLT, who did not receive NSBB therapy during the waiting period for LT. For the subsequent analysis, the group of patients receiving NSBB (n = 278) was divided into two subgroups: with the presence of a "therapeutic window" (n = 175), and without it (n = 103). The survival rate of patients was determined by the Kaplan - Mayer method. Predictors of mortality of patients receiving NSBB in the absence of a" therapeutic window "for NSBB were determined using the Cox proportional hazards model in the groups of patients with RA (n = 103) and non-RA (n = 175). Results. The survival rate of patients receiving NSBB in the presence of a" therapeutic window "for NSBB is significantly higher than in the group of patients receiving NSBB in WLLP while waiting for LT in the absence of a" therapeutic window " for NSBB (Log-Rank < 0.0001). The risk of death in patients with RA treated with NSBB was significantly higher than in patients with non-RA (HR = 2.285; CI 1.237 4.220; p = 0.008). The risk of death for patients treated with propranol was significantly different from carvedilol (HR = 2,152 and HR = 0.765; p = 0.042, respectively). Conclusion. The results of the study confirmed the hypothesis that there is a "therapeutic window" for NSBB when they are prescribed to patients with decompensated cirrhosis of the liver and included in the WLLP. The use of NSBB contributes to an increase in the mortality of patients with RA, regardless of the type of drug, in the case when the "closed therapeutic window" phase develops. In order to reduce the mortality of patients waiting for LT for several years due to acute organ deficiency, doctors who lead patients to WLLT should assess the risk and benefit of using NSBB
{"title":"Non-Selective Beta-Blockers in Liver Cirrhosis: the Effect of the \"Therapeutic Window\" and Patient Survival","authors":"V. L. Korobka, V. Pasechnikov, R. V. Korobka, A. Shapovalov","doi":"10.33978/2307-3586-2021-17-28-16-22","DOIUrl":"https://doi.org/10.33978/2307-3586-2021-17-28-16-22","url":null,"abstract":"Objectives of the study: to analyze the survival rate of patients who received and did not receive various drugs of the class of non-selective beta-blockers (NSBB) while waiting for liver transplantation (LT) on the waiting list for liver transplantation (WLLT), depending on the presence or absence of a \"therapeutic window\" for the appointment of NSBB; to determine risk factors for death when prescribing various representatives of the NSBB class in patients with refractory ascites (RA). Material and methods. The retrospective case-control study was conducted. The \"case\" group included 278 adult patients with decompensated liver diseases of various etiologies included in the WLLT, who were treated with NSBB while waiting for LT. The \"control\" group consisted of 72 patients with decompensated liver diseases of various etiologies included in the WLLT, who did not receive NSBB therapy during the waiting period for LT. For the subsequent analysis, the group of patients receiving NSBB (n = 278) was divided into two subgroups: with the presence of a \"therapeutic window\" (n = 175), and without it (n = 103). The survival rate of patients was determined by the Kaplan - Mayer method. Predictors of mortality of patients receiving NSBB in the absence of a\" therapeutic window \"for NSBB were determined using the Cox proportional hazards model in the groups of patients with RA (n = 103) and non-RA (n = 175). Results. The survival rate of patients receiving NSBB in the presence of a\" therapeutic window \"for NSBB is significantly higher than in the group of patients receiving NSBB in WLLP while waiting for LT in the absence of a\" therapeutic window \" for NSBB (Log-Rank < 0.0001). The risk of death in patients with RA treated with NSBB was significantly higher than in patients with non-RA (HR = 2.285; CI 1.237 4.220; p = 0.008). The risk of death for patients treated with propranol was significantly different from carvedilol (HR = 2,152 and HR = 0.765; p = 0.042, respectively). Conclusion. The results of the study confirmed the hypothesis that there is a \"therapeutic window\" for NSBB when they are prescribed to patients with decompensated cirrhosis of the liver and included in the WLLP. The use of NSBB contributes to an increase in the mortality of patients with RA, regardless of the type of drug, in the case when the \"closed therapeutic window\" phase develops. In order to reduce the mortality of patients waiting for LT for several years due to acute organ deficiency, doctors who lead patients to WLLT should assess the risk and benefit of using NSBB","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86285401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-15DOI: 10.33978/2307-3586-2021-17-28-10-14
E. Baulo, N. Belostotsky, O. Akhmadullina, S. Bykova, E. Sabelnikova, A. Parfenov
ENMP (enteropathy with impaired membrane digestion) is a new nosological form of pathology of the small intestine, which is based on a decrease in the activity of small intestine carbohydraz. The clinical picture of ENMA is very similar to irritable bowel syndrome, but it differs in the etiotropic relationship of symptoms with intolerance to products containing a lot of fermentable oligo -, di- and monosaccharides and polyols. The basis of the treatment of this pathology is the FODMAP diet, but this therapy only allows you to reduce the load on the enzymatic transport complexes, and not restore them. A new direction in the treatment of patients with EMF is our proposed system for restoring the activity of enzymes of the small intestine mucosa under the influence of the cytoprotector rebamipid. The use of rebamipid in the complex therapy of INMP contributes to an increase in the activity of small intestine carbohydraz and a decrease in symptoms associated with intolerance to short-chain carbohydrates FODMAP. The persistent positive effect of the drug is observed gradually over 8 weeks in patients who received the drug at a dose of 300 mg/day. With this treatment regimen, patients have an improvement in the tolerability of carbohydrate-containing foods, a decrease in flatulence, pain syndrome, and a tendency to normalize the stool has also been noted.
{"title":"The Effect of the Cytoprotector Rebamipid on the Activity of Disaccharidases in Patients with Enteropathy with Impaired Membrane Digestion","authors":"E. Baulo, N. Belostotsky, O. Akhmadullina, S. Bykova, E. Sabelnikova, A. Parfenov","doi":"10.33978/2307-3586-2021-17-28-10-14","DOIUrl":"https://doi.org/10.33978/2307-3586-2021-17-28-10-14","url":null,"abstract":"ENMP (enteropathy with impaired membrane digestion) is a new nosological form of pathology of the small intestine, which is based on a decrease in the activity of small intestine carbohydraz. The clinical picture of ENMA is very similar to irritable bowel syndrome, but it differs in the etiotropic relationship of symptoms with intolerance to products containing a lot of fermentable oligo -, di- and monosaccharides and polyols. The basis of the treatment of this pathology is the FODMAP diet, but this therapy only allows you to reduce the load on the enzymatic transport complexes, and not restore them. A new direction in the treatment of patients with EMF is our proposed system for restoring the activity of enzymes of the small intestine mucosa under the influence of the cytoprotector rebamipid. The use of rebamipid in the complex therapy of INMP contributes to an increase in the activity of small intestine carbohydraz and a decrease in symptoms associated with intolerance to short-chain carbohydrates FODMAP. The persistent positive effect of the drug is observed gradually over 8 weeks in patients who received the drug at a dose of 300 mg/day. With this treatment regimen, patients have an improvement in the tolerability of carbohydrate-containing foods, a decrease in flatulence, pain syndrome, and a tendency to normalize the stool has also been noted.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73369992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-15DOI: 10.33978/2307-3586-2021-17-28-80-84
L. D. Firsova, N. Bodunova, N. V. Romashkina
The article discusses the spectrum of the mental disorders that are potentially possible in obese patients, when they seek metabolic surgery; the personal characteristics of this category of patients are examined in detail, as well as questions of the motive and the purpose of the operation in terms of the degree of awareness of the decision made
{"title":"Features of Mental Sphere of Patients with Obesity Before and After Bariatric Surgery","authors":"L. D. Firsova, N. Bodunova, N. V. Romashkina","doi":"10.33978/2307-3586-2021-17-28-80-84","DOIUrl":"https://doi.org/10.33978/2307-3586-2021-17-28-80-84","url":null,"abstract":"The article discusses the spectrum of the mental disorders that are potentially possible in obese patients, when they seek metabolic surgery; the personal characteristics of this category of patients are examined in detail, as well as questions of the motive and the purpose of the operation in terms of the degree of awareness of the decision made","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77817960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：